Skip to main content
OpenTrials
Completed

NCT Number: NCT01281462

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

This is a study in adult subjects with complicated urinary tract infection (cUTI) comparing treatment with intravenous (IV) coadministered ceftaroline fosamil and NXL104 versus treatment with IV doripenem.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Investigational Site, Plovdiv, Bulgaria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must meet the following inclusion criteria:

  • Have pyuria (white blood cells in the urine)
  • Clinical signs and/or symptoms of cUTI (including acute pyelonephritis)
  • Have a pretreatment baseline urine culture specimen
  • The subject's infection would require initial treatment with IV antibiotics
  • The subject must require initial hospitalization to manage the cUTI by the standard of care.

Exclusion criteria

Subjects must NOT meet any of the following exclusion criteria:

  • History of any hypersensitivity or allergic reaction to any β-lactam (eg, cephalosporins, penicillins, carbapenems)
  • Confirmed fungal urinary tract infection
  • Intractable UTI anticipated to require more than 10 days of study drug therapy
  • Complete, permanent obstruction of the urinary tract\\
  • Permanent indwelling bladder catheter or instrumentation (including nephrostomy) or current urinary catheter that will not be removed during IV study drug administration
  • Suspected or confirmed perinephric or intrarenal abscess
  • Suspected or confirmed prostatitis
  • Ileal loops or vesico-ureteral reflux
  • Impairment of renal function including a calculated CrCl of < 30 mL/min, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria
  • Renal transplantation
  • Life expectancy less than 3 months
  • Evidence of significant hepatic, hematological, or immunologic disease or dysfunction
  • Past or current history of epilepsy or seizure disorder
  • Women who are pregnant or nursing

Treatment and study plan

Ceftaroline fosamil and NXL104 (q8h)

Drug

600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);

Other names: Ceftaroline fosamil and Avibactam(NXL104) (q8h)

Ceftaroline fosamil and NXL104 (q12h)

Drug

600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);

Other names: Ceftaroline fosamil and Avibactam(NXL104) (q12h)

Doripenem

Drug

500 mg doripenem IV q8h;

Placebo

Drug

On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.

Other names: placebo (saline)

Primary outcomes

  1. Microbiological response of Microbiologically Evaluable (ME) at Test of Cure (TOC)

    Time frame: 5 to 11 days after last dose of study drug

    The number and percentage of subjects in each treatment group recorded as having a favorable microbiological response in the ME Population at Test-of-Cure (TOC)

  2. Evaluate safety

    Time frame: from administration of first dose of study drug to the Late -Follow -Up (LFU) visit (28 to 42 days after administration of the last dose of study drug)

    Evaluate the safety of coadministered IV ceftaroline fosamil and NXL104 in subjects with cUTI. Summaries of AEs, SAEs, deaths, laboratory evaluations (hematology and coagulation studies, comprehensive metabolic panel, and urinalysis), vital signs, ECGs, and physical examinations will be provided for each treatment group.

Secondary outcomes

  1. Clinical response in CE at Test of Cure

    Time frame: 5 to 11 days after last dose of study drug

    The number and percentage of subjects in each treatment group classified as clinical cure Clinically Evaluable (CE) Population at TOC

Sponsors and collaborators

Lead sponsor

Forest Laboratories

Industry

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jan 24, 2011
Registry last updated
Feb 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.